The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.

Shares in private equity giant KKR (KKR) were higher today after it made a $1.2 billion takeover offer for Swedish biotechnology company ...

UnitedHealth reveals spending of $1.7 million on executive security following targeted violence concerns. Read more.

greater control over the biotech company’s operations. Pete Salzmann, Immunovant’s current CEO and board member, is retiring. He will be replaced by Eric Venker, Roivant’s current president ...

Analysts exoect revenue to rise by more than 180%, to $762 million, this year, and then grow another 45%, to $1.1 billion, next year, pushing the biotech company out of the red and into the black ...

Tilt your stock portfolio toward biotech companies now and you could stand to make substantial profits in the near future. You can also find cost-effective stocks under $20 to trade daily on the ...

DOHA: Qatar Free Zones Authority (QFZ) and BIOCAD– one of Russia’s leading biotechnology companies – yesterday signed a landmark Memorandum of Understanding, paving the way for the ...

The Federal Trade Commission on Monday sued Uber, accusing the ride-hailing and delivery company of deceptive billing and cancellation practices tied to its subscription service. The agency ...

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 million (around $16 million ...

The biotech is a specialist in messenger RNA technology, using mRNA to teach the body to make certain proteins that fight or protect against disease. The company's pipeline -- spanning programs ...

In a more recent escalation of this confrontation, the BIOSECURE Act was tabled in the US, which aims to prevent the contracting or extension of loans and grants with a “biotechnology company of ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer ...